



MH

#5


1614

Atty. Dkt. No. 041673-2053

RECEIVED
APR 25 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tuszynski, Mark H.
Title: METHODS FOR THERAPEUTIC USE
OF BRAIN DERIVED
NEUROTROPHIC FACTOR IN THE
ENTORHINAL CORTEX
Appl. No.: 10/039,078
Filing Date: 12/31/2001
Examiner: Unknown
Art Unit: 1614

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below. <div style="text-align: center;">Germaine Sarda (Printed Name)  (Signature) April 19, 2002 (Date of Deposit)</div>
--

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

RECEIVED
APR 25 2002
TECH CENTER 1600/2900

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Respectfully submitted,

Date 4-15-02

FOLEY & LARDNER
P.O. Box 80278
San Diego, California 92138-0278
Telephone: (858) 847-6720
Facsimile: (858) 792-6773

By Stacy L. Taylor

Stacy L. Taylor
Attorney for Applicant
Registration No. 34,842

Form PTO-1449
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

041673-2053

SERIAL NO.

10/039,878

Page 1 of 2

APPLICANT

Tuszynski, Mark H.

FILING DATE

12/31/2001

GROUP ART UNIT

1614

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A1	Andreason, et al., "Introduction and Expression of DNA Molecules in Eukaryotic Cells by Electroporation," <i>Biotechniques</i> , <u>6</u> (7):650-660 (1988)
	A2	Blaha, et al., "Brain-Derived Neurotrophic Factor Administration After Traumatic Brain Injury in the Rat Does Not Protect Against Behavioral or Histological Deficits," <i>Neuroscience</i> , <u>99</u> (3):483-493 (2000)
	A3	Capecci, M.R., "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells," <i>Cell</i> , <u>22</u> :479-488 (1980)
	A4	Conner, et al., "Distribution of Brain-Derived Neurotrophic Factor (BDNF) Protein and mRNA in the Normal Adult Rat CNS: Evidence for Anterograde Axonal Transport," <i>The Journal of Neuroscience</i> , <u>17</u> (7):2295-2313 (1997)
	A5	Croll, et al., "Brain-Derived Neurotrophic Factor Transgenic Mice Exhibit Passive Avoidance Deficits, Increased Seizure Severity and <i>In Vitro</i> Hyperexcitability in the Hippocampus and Entorhinal Cortex," <i>Neuroscience</i> , <u>93</u> (4):1491-1506 (1999)

EXAMINER

DATE CONSIDERED

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
041673-2053

SERIAL NO.
10/039,078

INFORMATION DISCLOSURE CITATION

APPLICANT

Tuszynski, Mark H.

FILING DATE

12/31/2001

GROUP ART UNIT

1614

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Naldini, et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector," *Science*, **272**:263-266 (1996)

A7

Pascual, et al., "BDNF induces glutamate release in cerebrocortical nerve terminals and in cortical astrocytes," *Neurochemistry*, 12(12):2673-2677 (2001)

A8

Tang, et al., "Genetic immunization is a simple method for eliciting an immune response," *Nature*, 356:152-154 (1992)

A9

Theofilopoulos, et al., "Parallel induction of the formation of dopamine and its metabolites with induction of tyrosine hydroxylase expression in foetal rat and human cerebral cortical cells by brain-derived neurotrophic factor and glial-cell derived neurotrophic factor," *Developmental Brain Research*, 127:111-122 (2001)

RECEIVED
APR 25 2002
TECH CENTER 1600/2900